

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for January 2022

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sandoz Canada Inc.	Sandoz Clonidine	Dixarit	CLONIDINE HCl	0.025 mg	tablet	02516217
Pharmaris Canada Inc	PRZ-Tadalafil	Cialis	TADALAFIL	2.5mg	tablet	02512262
Pharmaris Canada Inc	PRZ-Tadalafil	Cialis	TADALAFIL	5mg	tablet	02512270
Pharmaris Canada Inc	PRZ-Tadalafil	Cialis	TADALAFIL	10mg	tablet	02512289
Pharmaris Canada Inc	PRZ-Tadalafil	Cialis	TADALAFIL	20mg	tablet	02512297

Taro Pharmaceuticals Inc	Taro- Adapalene / Benzoyl Peroxide Forte	TactuPump Forte	ADAPALENE/ BENZOYL PEROXIDE	0.3 % / w/w & 2.5 % / w/w	topical gel	02505053
--------------------------------	---	--------------------	-----------------------------------	---------------------------------	----------------	----------